{
    "clinical_study": {
        "@rank": "119388", 
        "arm_group": [
            {
                "arm_group_label": "LY3127760 (Single)", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods."
            }, 
            {
                "arm_group_label": "Placebo (Single)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single oral dose of placebo administered in up to 2 of 3 study periods.  Placebo matches LY3127760 in appearance."
            }, 
            {
                "arm_group_label": "LY3127760 (Multiple)", 
                "arm_group_type": "Experimental", 
                "description": "Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days."
            }, 
            {
                "arm_group_label": "Placebo (Multiple)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance."
            }, 
            {
                "arm_group_label": "Celecoxib (Multiple)", 
                "arm_group_type": "Active Comparator", 
                "description": "Multiple oral doses of 400 mg celecoxib administered QD for 28 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purposes of this study are to evaluate the safety and how well the body handles\n      single and multiple doses of increasing strength of study drug,  LY3127760.  This study\n      includes three parts.  Part 3 may be initiated at sponsor's discretion, based on data from\n      Part 2. Participants will only enroll in 1 of the 3 study parts.  This study will last\n      approximately 7 to 13 weeks, depending on part.  Screening must be completed within 28 days\n      prior to enrollment."
        }, 
        "brief_title": "A Study of LY3127760 in Healthy Participants", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Overtly healthy males or females as determined by medical history and physical\n             examination\n\n          -  Male participants agree to use a reliable method of birth control during the study\n             and 3 months following the last dose of the investigational product\n\n          -  Female participants not of child-bearing potential\n\n          -  Have a body mass index of 18.5 to 32 kilograms per square meter (kg/m^2) inclusive\n\n          -  Are normotensive (defined as supine systolic blood pressure (BP) less than 140\n             millimeters of mercury [mm Hg] and diastolic BP less than 90 mm Hg) without use of\n             any antihypertensives\n\n        Exclusion Criteria:\n\n          -  Have known allergies to LY3127760, related compounds or any components of the\n             formulation, celecoxib or sulfonamides, or history of significant atopy. Participants\n             with known aspirin allergy or allergic reactions to nonsteroidal anti-inflammatory\n             drugs (NSAIDs) should also be excluded\n\n          -  Have any current or prior history of a significant gastrointestinal illness such as\n             peptic ulcer disease, gastrointestinal (GI) bleeding, chronic gastritis, inflammatory\n             bowel disease or chronic diarrhea\n\n          -  Have evidence of other chronic liver disease, including but not limited to chronic\n             alcoholic disease, nonalcoholic steatohepatitis, recent history (within 3 months of\n             screening) of acute viral hepatitis or chronic autoimmune hepatitis\n\n          -  Have used any NSAIDs, celecoxib, aspirin or acetaminophen (at doses greater than 1\n             gram per day), anticoagulants or antiplatelet agents within 14 days of admission\n\n        Part 2 and Part 3 only\n\n          -  Have 1 plus pretrial pitting edema or 2 plus ankle or pedal edema"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968070", 
            "org_study_id": "15181", 
            "secondary_id": "I7A-MC-EACA"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY3127760 (Single)", 
                    "Celecoxib (Multiple)", 
                    "Placebo (Single)", 
                    "LY3127760 (Multiple)", 
                    "Placebo (Multiple)"
                ], 
                "description": "Administered orally", 
                "intervention_name": "LY3127760", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Celecoxib (Multiple)", 
                "description": "Administered orally", 
                "intervention_name": "Celecoxib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LY3127760 (Single)", 
                    "Celecoxib (Multiple)", 
                    "Placebo (Single)", 
                    "LY3127760 (Multiple)", 
                    "Placebo (Multiple)"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Evansville", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "47710"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to Study Completion (approximately 7-13 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968070"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Single Dose LY3127760", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 144 hours post dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of Single Dose LY3127760", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 144 hours post dose"
            }, 
            {
                "measure": "Pharmacokinetics: Time of Maximum Concentration (tmax) of Single Dose LY3127760", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 144 hours post dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Curve (AUC[tau]) of Multiple Doses LY3127760", 
                "safety_issue": "No", 
                "time_frame": "Day 28"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of Multiple Doses LY3127760", 
                "safety_issue": "No", 
                "time_frame": "Post last dose on Day 28"
            }, 
            {
                "measure": "Pharmacokinetics: Time of Maximum Concentration (tmax) of Multiple Doses LY3127760", 
                "safety_issue": "No", 
                "time_frame": "Post last dose on Day 28"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}